Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer Relapsing on Standard Dose Alectinib
Open Access
- 18 December 2015
- journal article
- case report
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 11 (2), 256-260
- https://doi.org/10.1016/j.jtho.2015.10.010
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cordProceedings of the National Academy of Sciences, 2015
- Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain MetastasesJournal of Clinical Oncology, 2015
- Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and CeritinibJournal of Thoracic Oncology, 2015
- Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal CarcinomatosisThe Oncologist, 2015
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor AlectinibClinical Cancer Research, 2014
- Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastasesCancer Chemotherapy and Pharmacology, 2014
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 studyThe Lancet Oncology, 2014
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverageNature Medicine, 2014
- Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on CrizotinibJournal of Thoracic Oncology, 2014
- The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2013